NCT04776031已完成不适用
Evaluation of the R:GEN Laser System as an Intervention in Subjects With Early Stages of Age Related Macular Degeneration (AMD) for Safety and Exploratory Efficacy Outcomes
Lutronic Vision, Inc1 个研究点 分布在 1 个国家目标入组 31 人开始时间: 2021年2月15日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 31
- 试验地点
- 1
- 主要终点
- To access the safety and tolerability of the R:GEN Laser System in subjects with the early stages of AMD.
研究概览
简要总结
The purpose of this study is to assess the safety and tolerability of the R:GEN Laser System in subjects with the early stages of age-related macular degeneration.
详细描述
This clinical study is a prospective, single-center, single-arm, open-label, pilot study to evaluate the safety and tolerability of the R:GEN Laser System and to collect information on the severity of AMD in subjects with bilateral large drusen. All participants will receive the intervention at the baseline visit and at the 24-week visit. All participants will be evaluated at 24 and 48 weeks from the baseline visit.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults 50 years and over
- •Best Corrected Visual Acuity [BCVA] of 6/12 [20/40] or better in each eye
- •Bilateral large drusen: at least 1 druse ≥125 µm in each eye within an inner macular zone [a circle with a radius of 1500 µm centered on the fovea], and with or without pigment;
- •Ability and willingness to consent, receive laser treatment, and complete all visits
排除标准
- •Any evidence of definite reticular pseudo drusen [RPD] > 2-disc areas [DAs] as seen either by fundus autofluorescence [FAF] or near-infrared reflectance [NIR] enface imaging in each eye
- •Any evidence of geographic atrophy [GA] within the macula [a circle with a radius of 3000 microns centered on the fovea] excluding peripapillary atrophy
- •Any evidence of nascent GA, or worse evidence of atrophy (complete RPE and outer retinal atrophy) as determined by OCT: including the subsidence of the inner nuclear layer and outer plexiform layer [OPL], or the presence of a hyporeflective wedge-shaped band within the limits of the OPL, and accompanied by attenuation or absence of the RPE and hypertransmission into the choroid
- •Current choroidal neovascularization [CNV], (determined on multimodal imaging [MMI], but angiogram not required) or past evidence of CNV, including the presence of non-exudative macular neovascularization [NE-MNV] [determined by OCT-A]
- •Asymptomatic sub-retinal fluid [SRF] [a slither < 50 µm allowed]
- •Any current ocular disease or condition in the study eye including diseases affecting the optic nerve, the anterior chamber, and autoimmune or systemic inflammatory conditions in which there are ocular manifestations that either are undergoing or require treatment, or history of ocular disease within 3 months of screening
- •A central macular serous pigment epithelial detachment greater than 1000 µm in diameter; a central macular drusenoid detachment > 1000 µm with hyper reflective foci [HRF] and hypertransmission; or any central macular drusenoid pigment epithelial detachments >2000 µm
- •Previous retinal or ocular surgery within 3 months prior to screening, the effects of which may now or in the future complicate assessment of AMD
- •Any history of prior laser treatment to the retina
- •Any systemic medication known to be toxic to the retina
- •Known hypersensitivity to fluorescein or indocyanine green
- •Sensitivity to application of a contact lens
- •History or presence of uncontrolled glaucoma, ocular hypertension, or intraocular pressure > 24 mmHg
- •Cataract which in the opinion of the investigator limits evaluation of the retina or requires cataract surgery within 12 months
- •Pregnant or lactating women
- •Subject who is currently in a clinical study, or has received other active investigational therapy, within 30 days of the screening visit
- •Subject who is considered ineligible for this study in the investigator's medical judgment
研究组 & 干预措施
Laser Treatment
Experimental
Laser treatment using the R:GEN Laser System on Day 1 and at Week 24
干预措施: R:GEN Laser System (Device)
结局指标
主要结局
To access the safety and tolerability of the R:GEN Laser System in subjects with the early stages of AMD.
时间窗: up to 48 weeks
Incidences of Serious Adverse Events, Serious Adverse Device Effects, Unanticipated Serious Adverse Device Effects
次要结局
- To evaluate the progression in severity of AMD after treatment with the R:GEN Laser System at 24 weeks and 48 weeks post-treatment.(24 weeks and 48 weeks post-treatment)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Genotoxicity Assessment for Patients Undergoing Radiation TreatmentNeoplasmsNCT00167427Yuhchyau Chen47
已完成
4 期
Presbyopic Supracor Treatment for Near Myopic/Hyperopic Pseudophakic EyesPresbyopiaHyperopiaMyopiaNCT01387360Technolas Perfect Vision GmbH33
已完成
不适用
Measurement and Treatment of Back PainBack PainNCT06245863State University of Minas Gerais50
已完成
2 期
Effects of laser on postoperative sensitivityPost operative sensitivity.IRCT2012072810425N1Vice chancellor for research, Mashhad University of Medical Sciences24
撤回
不适用
Thulium Laser and Topical Platelet Rich Plasma (PRP) vs. PRP Injection for the Treatment of Male Androgenetic AlopeciaAndrogenetic AlopeciaNCT05129254Montefiore Medical Center